These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 35257901)
1. Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia. Roskoski R Pharmacol Res; 2022 Apr; 178():106156. PubMed ID: 35257901 [TBL] [Abstract][Full Text] [Related]
2. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation. Monestime S; Al Sagheer T; Tadros M Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958 [TBL] [Abstract][Full Text] [Related]
3. SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia. Wang D; Zheng Y; Li J; Wu H; Li X; Tang Y; Liu Y; Li J; Sun R; Zhou Y; Sun J; Yang Y Eur J Pharmacol; 2017 Sep; 811():117-124. PubMed ID: 28595903 [TBL] [Abstract][Full Text] [Related]
5. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133 [TBL] [Abstract][Full Text] [Related]
6. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia. Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722 [TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Jabbour E; Kantarjian H Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859 [TBL] [Abstract][Full Text] [Related]
8. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Manley PW; Barys L; Cowan-Jacob SW Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322 [TBL] [Abstract][Full Text] [Related]
9. Targeted drugs in chronic myeloid leukemia. Gora-Tybor J; Robak T Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651 [TBL] [Abstract][Full Text] [Related]
10. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928 [TBL] [Abstract][Full Text] [Related]
11. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778 [TBL] [Abstract][Full Text] [Related]
12. Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation. Liu J; Zhang Y; Huang H; Lei X; Tang G; Cao X; Peng J Chem Biol Drug Des; 2021 Mar; 97(3):649-664. PubMed ID: 33034143 [TBL] [Abstract][Full Text] [Related]
13. Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib. Häselbarth L; Karow A; Mentz K; Böttcher M; Roche-Lancaster O; Krumbholz M; Jitschin R; Mougiakakos D; Metzler M Cancer Immunol Immunother; 2023 Jun; 72(6):1661-1672. PubMed ID: 36602564 [TBL] [Abstract][Full Text] [Related]
14. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Jabbour E; Kantarjian H Am J Hematol; 2024 Nov; 99(11):2191-2212. PubMed ID: 39093014 [TBL] [Abstract][Full Text] [Related]
15. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
16. Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the Abl Al Shahrani M; Gahtani RM; Abohassan M; Alasmari S; Makkawi M Med Oncol; 2023 Oct; 40(11):316. PubMed ID: 37789230 [TBL] [Abstract][Full Text] [Related]
17. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693 [TBL] [Abstract][Full Text] [Related]
18. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity. Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930 [TBL] [Abstract][Full Text] [Related]
19. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Syed YY; McCormack PL; Plosker GL BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842 [TBL] [Abstract][Full Text] [Related]